Tablet Amitriptyline 10 milligrams

Small molecule

Tablet Amitriptyline 10 milligrams is one of 35 small molecule programs targeting Dyspepsia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyspepsiaActive, not recruiting

DyspepsiaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

99 competitors in Dyspepsia

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Phase 3

2 2

Tofranil

Sanofi

Phase 3

1 3

Elavil

AstraZeneca

Phase 3

1 4

Pamelor

SSpecgx

Phase 3

1 5

Neurontin

VViatris Specialty LLC

Phase 3

1 6

Domperidone

Johnson & Johnson

Phase 3

3 7

Xifaxan

SSalix

Phase 2

3 8

Nereus

VVanda Pharmaceuticals

Phase 2

1 9

Aciphex

Akero Therapeutics

Phase 2

1 10

GW679769

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dyspepsia1 trial

Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia

Recruiting·MMd. Moktadirul Hoque Shuvo·Phase 2/3·NCT07008235·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tablet Amitriptyline 10 milligrams. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tablet Amitriptyline 10 milligrams compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tablet Amitriptyline 10 milligrams. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Md. Moktadirul Hoque Shuvo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: MMd. Moktadirul Hoque Shuvo

Tablet Amitriptyline 10 milligrams

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dyspepsia1 trial

References

Drug Info

Quick Facts

Related News